Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.
复制标题
DOI：
10.1007/s10549-011-1450-1
复制
发表时间：
2011-06
影响因子：
3.8
通讯作者：
Ubel, Peter A.
中科院分区：
文献类型：
--
作者：
Fagerlin, Angela;Dillard, Amanda J.;Smith, Dylan M.;Zikmund-Fisher, Brian J.;Pitsch, Rosemarie;McClure, Jennifer B.;Greene, Sarah;Alford, Sharon Hensley;Nair, Vijayan;Hayes, Daniel F.;Wiese, Cheryl;Ubel, Peter A.
尽管他莫昔芬可以预防原发性乳腺癌，但很少有女性将其用作预防措施。第二种选择，雷洛昔芬，最近已经获得批准。这项研究的目的是在阅读了一份描述了每种药物的风险和益处的决策辅助材料后，确定女性对他莫昔芬和雷洛昔芬的兴趣。来自两个大型健康维护组织的乳腺癌风险为5年的妇女≥1.66被随机分为两组，接受决策援助和常规护理。在阅读了一份讨论他莫昔芬和雷洛昔芬风险和益处的在线决策辅助工具后，女性完成了与他莫昔芬和雷洛昔芬相关的风险认知、决策冲突、行为意图和实际行为的测量。干预3个月后，8.1%的参与者寻求有关乳腺癌预防药物的更多信息，1.8%的参与者向他们的医生咨询过他莫昔芬和/或雷洛昔芬。大多数人(54.7%)决定不服用这两种药物，0.5%的人开始服用雷洛昔芬，没有人开始服用他莫昔芬。参与者并不特别担心服用他莫昔芬或雷洛昔芬，也没有看到服用这些药物的显著好处。超过50%的人认为，如果他们服用他莫昔芬或雷洛昔芬，他们患乳腺癌的风险没有变化。在阅读了关于他莫昔芬和雷洛昔芬的DA后，很少有女性对服用这两种乳腺癌预防药物感兴趣。
Although tamoxifen can prevent primary breast cancer, few women use it as a preventive measure. A second option, raloxifene, has recently been approved. The objective of the study was to determine women’s interest in tamoxifen and raloxifene after reading a decision aid describing the risks and benefits of each medication. Women with 5-year risk of breast cancer ≥1.66 from two large health maintenance organizations were randomized to receive a decision aid versus usual care. After reading an on-line decision aid that discussed the risks and benefits of tamoxifen and raloxifene, women completed measures of risk perception, decisional conflict, behavioral intentions and actual behavior related to tamoxifen and raloxifene. 3 months following the intervention, 8.1% of participants had looked for additional information about breast cancer prevention drugs and 1.8% had talked to their doctor about tamoxifen and/or raloxifene. The majority, 54.7%, had decided to not take either drug, 0.5% had started raloxifene, and none had started tamoxifen. Participants were not particularly worried about taking tamoxifen or raloxifene and did not perceive significant benefits from taking these drugs. Over 50% did not perceive a change in their risk of getting breast cancer if they took tamoxifen or raloxifene. After reading a DA about tamoxifen and raloxifene, few women were interested in taking either breast cancer prevention drug.
登录
查看更多内容
DOI：
10.1111/j.1467-842x.2003.tb00397.x
发表时间：
2003-06-01
影响因子：
3.5
作者：
Donovan, RJ;Jalleh, G;Jones, SC
通讯作者：
Jones, SC
妇女关于他莫昔芬预防乳腺癌的决定：对量身定制的决策援助的反应。
影响因子：
3.8
作者：
Fagerlin, Angela;Zikmund-Fisher, Brian J.;Smith, Dylan M.;Nair, Vijayan;Derry, Holly A.;McClure, Jennifer B.;Greene, Sarah;Stark, Azadeh;Alford, Sharon Hensley;Lantz, Paula;Hayes, Daniel F.;Wiese, Cheryl;Zweig, Sarah Claud;Pitsch, Rosemarie;Jankovic, Aleksandra;Ubel, Peter A.
通讯作者：
Ubel, Peter A.
DOI：
10.1046/j.1369-6513.2003.00195.x
发表时间：
2003-03-01
期刊：
Health expectations : an international journal of public participation in health care and health policy
影响因子：
--
作者：
Stacey, Dawn;O'Connor, Annette M;Verma, Shailendra
通讯作者：
Verma, Shailendra
DOI：
10.1001/jama.1995.03520280048038
发表时间：
1995-01-25
影响因子：
120.7
作者：
REDELMEIER, DA;SHAFIR, E
通讯作者：
SHAFIR, E
影响因子：
6.2
作者：
Melnikow, J;Paterniti, D;Henderson, S
通讯作者：
Henderson, S